financetom
Business
financetom
/
Business
/
Odisha govt asks ArcelorMittal-Nippon to revive steel plant in Paradip
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Odisha govt asks ArcelorMittal-Nippon to revive steel plant in Paradip
Jan 29, 2020 2:04 PM

The Odisha government has reached out to ArcelorMittal-Nippon, asking them to set up a 3 million tonnes per annum (mtpa) capacity steel plant in the state.

Share Market Live

NSE

The erstwhile promoter of Essar Steel had signed a MoU with Odisha government in 2005 for building a steel plant in Paradip, which could cost about Rs 12,000 crore.

“Original MoU with Essar Steel was for setting up of 3MTPA steel plant at Paradip in Odisha, it will give a major boost to our target of reaching 50 percent value addition on minerals in the state by 2030.”

The land for the plant is already with the company and talks are at a preliminary stage with ArcelorMittal Nippon, said Hemant Sharma, principal secretary, industry, Odisha government.

The takeover of the Essar Steel by ArcelorMittal-Nippon has given the company access to a developing market with 10MTPA steel-making capacity on the west coast Hazira, Gujarat.

It also has the advantage of a pellet plant, beneficiation plant and slurry pipeline in Odisha, which will give the company an edge on the east coast as well.

"Our industrial strategy for India includes an initial investment of more than Rs 8,000 crore to improve existing operations, efficiency, technology, product quality, and profitability. And, we are also committed to growing the business further, reaching shipments of 8.5 million tonnes and a long-term aspiration of 12-15 million tonnes" said Aditya Mittal, president and CFO, ArcelorMittal, and chairman of ArcelorMittal-Nippon (AM/NS) India.

ArcelorMittal-Nippon joint venture had made an initial payment of Rs 42,000 crore for the acquisition of Essar Steel under Insolvency and Bankruptcy Code (IBC) in December 2019.

First Published:Jan 29, 2020 11:04 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
EV maker Polestar recalls 27,816 US vehicles due to rearview image issue
EV maker Polestar recalls 27,816 US vehicles due to rearview image issue
May 26, 2025
May 2 (Reuters) - Electric vehicle maker Polestar is recalling 27,816 cars in the United States over an issue with the rearview camera, the U.S. National Highway Traffic Safety Administration (NHTSA) said on Friday. The NHTSA said the rearview camera image in the certain Polestar 2 vehicles may not display when the car is placed in reverse, increasing risk of...
EV maker Polestar recalls 27,816 US vehicles due to rearview image issue
EV maker Polestar recalls 27,816 US vehicles due to rearview image issue
May 26, 2025
(Reuters) -Electric vehicle maker Polestar is recalling 27,816 cars in the United States over an issue with the rearview camera, the U.S. National Highway Traffic Safety Administration (NHTSA) said on Friday. The NHTSA said the rearview camera image in the certain Polestar 2 vehicles may not display when the car is placed in reverse, increasing risk of a crash. As...
Genmab to Seek FDA Review of Follicular Lymphoma Combination Therapy
Genmab to Seek FDA Review of Follicular Lymphoma Combination Therapy
May 26, 2025
05:26 AM EDT, 05/02/2025 (MT Newswires) -- Genmab ( GMAB ) said late Thursday it plans to submit a supplemental biologics license application in H1 to the US Food and Drug Administration for epcoritamab in combination with rituximab and lenalidomide for patients with relapsed or refractory follicular lymphoma. The decision is based on findings from a phase 3 study, which...
Copyright 2023-2026 - www.financetom.com All Rights Reserved